Article Details
Retrieved on: 2025-09-09 13:03:37
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
- BioNTech and BMS's dual-pathway bispecific Pumitamig targets PD-L1 and VEGF-A for ES-SCLC, showing 76.3% response rate in Phase II trials. - The ...
Article found on: www.ainvest.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here